Equites Radar

LH · Labcorp Holdings Inc.

Diagnostics & ResearchUnited StatesAnalyst view: Buy

$296.77

+4.34% last session

End-of-day data · updated 2026-07-28

Bullish5 bullish · 1 bearish technical signals
Consensus: Buy (1.63 from 17 analysts)
To mean target: +5.2%

Market cap

$25B

Enterprise value

$31B

Trailing P/E

26.7

Forward P/E

15.5

Dividend yield

1.0%

Beta

0.86

Avg volume

1M

Employees

71K

2D change

5D change

3.49%

10D change

6.29%

30D change

10.94%

60D change

15.81%

MTD change

6.09%

YTD change

20.68%

Analyst Outlook

Consensus ratingBuy
Recommendation mean (1–5)1.63
Covering analysts17
Mean price target$312.35
Low price target$270.00
Upside to mean target+5.2%

Analyst estimates change daily — follow the shifts on the Estimate Trends page.

Technical Analysis

RSI (14)79.1
50-day MA$269.65
200-day MA$266.64
Price vs 50-day MA+16.5%
Price vs 200-day MA+17.9%
MACD histogram2.62
Volume vs 3-month avg1.6×
52w low $244.6952w high $314.23

Analyst sentiment over time — LH

Rec Mean (blue, left — higher = more bullish) vs. price targets (right).

Investment Bank Ratings as of 2026-07-13

Latest call per bank · past 12 months

Bank of America

Buy

$320

+7.8% vs price
▲ raised from $300Maintains · 2026-07-13

JP Morgan

Overweight

$330

+11.2% vs price
▲ raised from $319Maintains · 2026-02-18

UBS

Buy

$320

+7.8% vs price
▼ cut from $325Maintains · 2025-10-29

Barclays

Equal-Weight

$290

-2.3% vs price
▲ raised from $275Maintains · 2025-10-02

Recent rating actions

DateFirmActionRatingPrice target
2026-07-13Bank of AmericaMaintainsBuy$300 $320
2026-07-13BairdMaintainsOutperform$335 $338
2026-04-08Evercore ISI GroupMaintainsOutperform$280 $300
2026-02-24Piper SandlerMaintainsNeutral$270 $300
2026-02-18JP MorganMaintainsOverweight$319 $330
2026-02-18BairdMaintainsOutperform$313 $326
2026-02-06JP MorganMaintainsOverweight$317 $319
2025-11-07JP MorganMaintainsOverweight$291 $317

Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.

Signal Summary as of 2026-07-28

  • RSI (14): RSI is 79 — overbought territory; the recent run-up may be due for a pause.
  • Price vs 50-day MA: Trading 16.5% above the 50-day MA ($269.65).
  • Price vs 200-day MA: Trading 17.9% above the 200-day MA ($266.64).
  • MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
  • MACD (12,26,9): MACD histogram is positive (+2.62) — short-term momentum is improving.
  • 52-week range: Price is within 5% of the 52-week high ($314.23).

LH Price Chart

Loading chart for LH

Fundamentals

Revenue (TTM)$14B
EBITDA$2.0B
Free cash flow$1.0B
Operating cash flow$2.0B
Book value / share$106.06
Net debt / EBITDA2.8
WACC9.0%
Revenue growth6.00%
Earnings growth33.00%

About Labcorp Holdings Inc.

Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing service, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, it offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI enabled Test Selection, a generative AI enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. It has a strategic collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics; and Alliance for Clinical Trials in Oncology to advance national clinical trial for patients diagnosed with colorectal cancer. The company was founded in 1995 and is headquartered in Burlington, North Carolina.

More in Diagnostics & Research

Screen LH against the full market on the Radar →

Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.